12-14 In phase III clinical studies in which exenatide was administered concomitantly with metformin, an SU, or metformin plus an SU, 48% of the 483 patients receiving exenatide 10 mcg twice daily reported nausea compared to 18% of the 483 patients receiving placebo
KLOW Stack Dosage Chart This KLOW Stack dosage chart summarizes the common pre-blended 80 mg vial schedule, including the 50:10:10:10 GHK-Cu, KPV, BPC-157, and TB-500 ratio, the 3 mL reconstitution setup, and the once-daily reference dose range
Semaglutide is a GLP-1 receptor agonist (targets one receptor pathway), while tirzepatide is a dual GIP/GLP-1 receptor agonist (targets two receptor pathways)
Everything is moving in the wrong direction
If you can only eat 800 calories in a day, make 350-400 of those calories come from protein sources
It is important to emphasize that if shortness of breath develops during GLP-1 treatment, it should not be automatically attributed to the medication without thorough clinical evaluation